No association has been found with assay and decreased chemotherapy use in older patients, researchers report. Oncotype DX is a 21-gene assay used to help estimate the likelihood of recurrence in women with early-stage breast cancer and, thus, determine those who may or may not benefit from adjuvant chemotherapy.